These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24420152)

  • 1. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
    Sun Y; Ding H; Liu X; Li X; Li L
    Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
    Ding H; Sun Y; Hou Y; Li L
    Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
    Sun Y; Ding H; Li XQ; Li L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):135-9. PubMed ID: 24791791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
    Reed DE; Shokat KM
    Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
    Li D; Yang J; Ma H; Sun C; Feng R
    J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
    Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
    Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
    Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
    Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
    Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
    Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
    Ali M; Kamjoo M; Thomas HD; Kyle S; Pavlovska I; Babur M; Telfer BA; Curtin NJ; Williams KJ
    Mol Cancer Ther; 2011 Dec; 10(12):2320-9. PubMed ID: 21926192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
    Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
    Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    Guney Eskiler G; Ozturk M
    Cell Signal; 2022 Mar; 91():110229. PubMed ID: 34958867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells.
    Ahmed SA; Mendonca P; Messeha SS; Oriaku ET; Soliman KFA
    Molecules; 2023 Dec; 29(1):. PubMed ID: 38202644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.